House panel supports 12-year exclusivity for biotech drugs

08/3/2009 | Wall Street Journal, The

The House Energy and Commerce Committee voted 47-11 to approve a measure that would give 12 years of market protection to brand-name biotech medicines. The amendment "takes a balanced approach between innovation, cost savings for consumers and safety," said a spokeswoman for Rep. Jay Inslee, D-Wash., one of the sponsors of the bill.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA